MET and cancer: Moreover, GC-MSC could robustly express hepatocyte growth factor (HGF) as ligand of c‐MET to trigger phosphorylation of its downstream signaling cascade in cancer cells, and aberrant HGF/c-MET axis has been well-established to be critical for GC progression (38).